Grace Therapeutics, Inc GRCE

acasti

[alanmar1]

As a tolerant investor in ACST for many years I wish to raise the following point.  

ACST is cash poor and needs a partner.

Have ACST considered approaching one of the large Chinese pharma organizations.

China has enough health problems of it's own for which CarePre could be the answer to justify acquisition and this alone could support a purchase price that would satisfy most, if not all, investors.  

Whether or not the FDA issue an NDA or not China would then have a product that would not only help Chinese patients but would also provide them with a product that has worldwide market potential.

[Rosmorduc]

I agree. Path to NDA would be beautiful and it will get there but in the interim, the smart people know VERY WELL based on the studies that CAPRE works and will lenghten lives and save lives.  So once T2 is out, there could possibly be a large player, perhaps offshore, that can come pick this up for 10$ a share and make billions of dollars with CAPRE worldwide.  Bottom line: CAPRE

[postie1]

If they could just have had their act together "Doctors warn of lasting heart complications With new evidence and data on the virus emerging almost weekly, health officials now have another warning: the risk of death from coronavirus-related heart damage seems to be far greater than previously thought, the American Heart Association said. "Basically this virus can put some

[Francine01]

Management is fully aware of the china market. they had a $125M deal in 2017 for the China market. They decided ph3 results to gamble that the value would significantly more than the offer on the table. After T2 results, only god knows what will be the outcome for an NDA and China market.  My view is that Acasti is at the bottom and all bad news are fully priced. T2 will be better and we